Pfizer Ltd. (PFIZER) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 970356,
    "name": "Pfizer",
    "stock_name": "Pfizer",
    "full_name": "Pfizer Ltd.",
    "name_url": "stocks-analysis/pfizer",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "4,613.50",
    "chg": -112.4,
    "chgp": "-2.38%",
    "dir": -1,
    "prev_price": "4,725.90",
    "mcapval": "21,233.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 500680,
    "symbol": "PFIZER",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE182A01018",
    "curr_date": "May 13",
    "curr_time": "",
    "bse_nse_vol": "36.11 k",
    "exc_status": "Active",
    "traded_date": "May 13, 2026",
    "traded_date_str": "2026 05 13",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/pfizer-970356-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Pfizer Ltd. Q4 FY26: Modest Growth Amid Margin Recovery, But Valuation Concerns Persist",
        "link": "https://www.marketsmojo.com/news/result-analysis/pfizer-ltd-q4-fy26-modest-growth-amid-margin-recovery-but-valuation-concerns-persist-3990012",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Pfizer_quaterlyResult_3990012.png",
        "date": "2026-05-13 18:03:30",
        "description": "Pfizer Ltd., the Indian arm of the global pharmaceutical giant, reported a net profit of ₹199.82 crores for Q4 FY26 (March 2026 quarter), marking a substantial ▲40.89% quarter-on-quarter increase from ₹141.84 crores in Q3 FY26. However, on a year-on-year basis, the performance remained subdued with a ▼39.61% decline compared to ₹330.94 crores in Q4 FY25. The stock, currently trading at ₹4,606.40 with a market capitalisation of ₹21,233 crores, has declined ▼2.59% in the latest trading session, reflecting investor concerns about the company's long-term growth trajectory and premium valuation."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-3985370",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PfizerLtd_mojoScore_3985370.png",
        "date": "2026-05-11 10:10:49",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "When is the next results date for Pfizer Ltd.?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-pfizer-ltd-3980459",
        "imagepath": "",
        "date": "2026-05-07 23:17:00",
        "description": "The next results date for Pfizer Ltd. is scheduled for 12 May 2026...."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-3969990",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PfizerLtd_mojoScore_3969990.png",
        "date": "2026-04-30 10:10:38",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Pfizer Ltd. Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/pfizer-ltd-technical-momentum-shifts-amid-mixed-market-signals-3955115",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PfizerLtd_technicaldot_3955115.png",
        "date": "2026-04-21 08:05:28",
        "description": "Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a cautious outlook for investors amid mixed signals."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-3952878",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PfizerLtd_mojoScore_3952878.png",
        "date": "2026-04-19 10:10:37",
        "description": "Pfizer Ltd. is currently rated Sell by MarketsMOJO, a rating that was last updated on 29 December 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the stock’s current position as of 19 April 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-3937348",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PfizerLtd_mojoScore_3937348.png",
        "date": "2026-04-08 10:10:35",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 April 2026, providing investors with an up-to-date view of the company's performance and outlook."
      },
      {
        "title": "Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/pfizer-ltd-technical-momentum-shifts-to-bearish-amid-market-volatility-3923441",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/PfizerLtd_technicaldot_3923441.png",
        "date": "2026-03-30 08:02:33",
        "description": "Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a bearish stance. This transition is underscored by deteriorating technical indicators including MACD, Bollinger Bands, and moving averages, signalling increased selling pressure despite some bullish volume trends. Investors should carefully analyse these developments as the stock navigates a challenging market environment."
      },
      {
        "title": "Pfizer Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/pfizer-ltd-is-rated-sell-by-marketsmojo-3921500",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/PfizerLtd_mojoScore_3921500.png",
        "date": "2026-03-28 10:10:15",
        "description": "Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      }
    ],
    "total": 361,
    "sid": "970356",
    "stock_news_url": "https://www.marketsmojo.com/news/pfizer-970356"
  },
  "announcements": [
    {
      "details": "Pfizer Limited has submitted to the Exchange a copy of Disclosure of Related Party Transaction for the half year ended September 30, 2019.",
      "source": "NSE",
      "caption": "Pfizer Limited - Other General Purpose",
      "datetime": "27-Nov-2019"
    },
    {
      "details": "Pfizer Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Pfizer Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "13-Nov-2019"
    },
    {
      "details": "Pfizer Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates",
      "source": "NSE",
      "caption": "Pfizer Limited - Analysts/Institutional Investor Meet/Con. Call Updates",
      "datetime": "05-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Pfizer Ltd. has declared <strong>350%</strong> dividend, ex-date: 09 Jul 25",
          "dt": "2025-07-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Pfizer Ltd. Q4 FY26: Modest Growth Amid Margin Recovery, But Valuation Concerns Persist

2026-05-13 18:03:30

Pfizer Ltd., the Indian arm of the global pharmaceutical giant, reported a net profit of ₹199.82 crores for Q4 FY26 (March 2026 quarter), marking a substantial ▲40.89% quarter-on-quarter increase from ₹141.84 crores in Q3 FY26. However, on a year-on-year basis, the performance remained subdued with a ▼39.61% decline compared to ₹330.94 crores in Q4 FY25. The stock, currently trading at ₹4,606.40 with a market capitalisation of ₹21,233 crores, has declined ▼2.59% in the latest trading session, reflecting investor concerns about the company's long-term growth trajectory and premium valuation.

Read full news article

Pfizer Ltd. is Rated Sell by MarketsMOJO

2026-05-11 10:10:49

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

When is the next results date for Pfizer Ltd.?

2026-05-07 23:17:00

The next results date for Pfizer Ltd. is scheduled for 12 May 2026....

Read full news article

Pfizer Ltd. is Rated Sell

2026-04-30 10:10:38

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Pfizer Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-04-21 08:05:28

Pfizer Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. This transition is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest a cautious outlook for investors amid mixed signals.

Read full news article

Pfizer Ltd. is Rated Sell by MarketsMOJO

2026-04-19 10:10:37

Pfizer Ltd. is currently rated Sell by MarketsMOJO, a rating that was last updated on 29 December 2025. While this rating change occurred several months ago, the analysis and financial metrics presented here reflect the stock’s current position as of 19 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Pfizer Ltd. is Rated Sell by MarketsMOJO

2026-04-08 10:10:35

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

Read full news article

Pfizer Ltd. Technical Momentum Shifts to Bearish Amid Market Volatility

2026-03-30 08:02:33

Pfizer Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish to a bearish stance. This transition is underscored by deteriorating technical indicators including MACD, Bollinger Bands, and moving averages, signalling increased selling pressure despite some bullish volume trends. Investors should carefully analyse these developments as the stock navigates a challenging market environment.

Read full news article

Pfizer Ltd. is Rated Sell by MarketsMOJO

2026-03-28 10:10:15

Pfizer Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

View All News